|Tel||+44 (0)1865 223451|
- Rehabilitation Research in Oxford (RRIO) Research Group
OCTRU Lead Medical Statistician
Expert in statistics and clinical trial methodology
I am an experienced senior statistician working with medical professionals to design, achieve grant funding, conduct, analyse and report randomised clinical trials. I oversee an expanding group of medical statisticians at the Oxford Clinical Trials Research Unit – embedded in the Centre for Statistics in Medicine (CSM) – where I provide statistical management and input into all five therapeutic streams: musculoskeletal and rheumatology, rehabilitation and trauma, surgical interventions and oncology. I also teach short courses, workshops and hour-long training bites on how to conduct a trial, and run the annual week-long CSM Randomised Clinical Trials Course.
My expertise range from simple standard two-arm parallel group trials to complex multi-arm trials, factorial trials and trials within a cohort. I have worked on all aspects of intervention development, from early phase and pilot/feasibility studies to phase III pragmatic randomised trials, investigating drug and medical device interventions as well as complex rehabilitation and surgical interventions.
I provide independent statistical expertise to external bodies such as a NICE Technology Appraisal Committee, Data and Safety Monitoring Committees and Trial Steering Committees. I am the statistical editor of Maturitas and provide independent peer review for grant applications, final study reports and journal publications. I am a member of the UKCRC Statistics Group and the NIHR Statistics Group.
My career started in medical statistics in Liverpool at the Congenital Malformations Registry and then moved to Oxford to explore the geographical distribution of childhood cancers around nuclear installations. I joined CSM as an oncology trial statistician in 2007 and was appointed OCTRU Lead Statistician in 2013.
In my spare time, I am an obsessive patchwork and quilter, and enjoy reading, walking, geology, theatre trips and holidays to mountains and islands.
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
Dutton SJ. et al, (2014), Lancet Oncol, 15, 894 - 904
Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial.
Spathis A. et al, (2014), J Clin Oncol, 32, 1882 - 1888
Multicenter randomized controlled trial of conventional versus laparoscopic surgery for colorectal cancer within an enhanced recovery programme: EnROL.
Kennedy RH. et al, (2014), J Clin Oncol, 32, 1804 - 1811
Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes.
Boutron I. et al, (2010), JAMA, 303, 2058 - 2064
FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer.
Dutton SJ. et al, (2014), BMC Cancer, 14
Gefitinib and EGFR gene copy number aberrations in esophageal cancer
Petty RD. et al, (2017), Journal of Clinical Oncology, 35, 2279 - 2287
Study protocol: A multi-centre, double blind, randomised,
placebo-controlled, parallel group, phase II trial (RIDD) to
determine the efficacy of intra-nodular injection of anti-TNF to
control disease progression in early Dupuytren’s disease, with
an embedded dose response study
Nanchahal J. et al, (2017), Wellcome Open Research
Machine perfusion in liver transplantation: practical issues to consider in the design and conduct of a complex multinational interventional trial and the potential impact on the analysis
Chiocchia V. et al, (2017), Trials, 18
Data Monitoring Committee overseeing multiple international randomised controlled trials
Chiocchia V. et al, (2017), Trials
Characteristics and Dissemination of Phase I Trials Approved by a UK Regional Office in 2012
Odutayo A. et al, (2017), JAMA